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 Resistance to abiraterone or enzalutamide after previous hormonal therapy is 
increasingly likely and cross-resistance often occurs when these two agents are given 
sequentially. Blood-based analysis of AR mRNA splice variants and AR genomic mutations 
may aid ourThus, an increased understanding of the mechanisms of resistance to these drugs 
in order to is required in order to better manage patients with castration-resistant prostate 
cancer. 
 
Refers to Bernemann, C. et al. Expression of AR-V7 in circulating tumour cells does not 
preclude response to next generation androgen deprivation therapy in patients with castration r
esistant prostate cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.07.021 (2016) 
 
Abiraterone and enzalutamide are now widely used as standard treatments for castration- 
resistant prostate cancer (CRPC). Overall, >90% of patients show a decline in serum PSA 
levels when treatment is initiated as first-line CRPC 
therapy, but increasing lines of previous hormonal therapy amplifiesincrease the likelihood of 
primary resistance1. Moreover>20% of men experience a PSA concentration decline with the 
second agent when abiraterone or enzalutamide are used sequentially. A change in PSA levels 
is commonly used as an objective end point in phase II clinical trials (especially those testing 
androgen-receptor (AR)-targeting compounds)2, but the duration of benefit for abiraterone or en
zalutamide is variable even for men who respond to treatment — some men experience an exc
eptional long-term response, 
continuing treatment for several years, whereas other patients progress clinically within 
months. Thus, we urgently need to understand the mechanisms of resistance to abiraterone 
and enzalutamide and develop biomarker approaches that can be used to improve the 
management of patients with CRPC.  
 
AR splice variants (AR-Vs) and/or genomic AR aberrations are associated with resistance to 
abiraterone or enzalutamide. AR-Vs lacking the ligand-binding domain (LBD) maintain AR- 
regulated transcription in multiple in vitro and in vivo enzalutamide and/or abiraterone-resistant 
models3. Detection of the AR-V7 splice 
variant in circulating tumour cells (CTCs) from men with CRPC is strongly associated with a 
reduced rate of PSA decline and decreased progression-free and overall survival with 
abiraterone or enzalutamide treatment4,5. 
 
Similarly, detection of AR amplification or specific point mutations in circulating cell-free DNA 
(ccfDNA) is also associated with resistance to abiraterone or enzalutamide6-9. Liquid biopsies th
at define AR-Vs and/or AR genomic status at the same time (for 
example integrated AR analysis at the mRNA and DNA level) could, therefore, identify patients li
kely to derive limited benefit from potent AR-LBD targeting with drugs such as abiraterone and e
nzalutamide and pre-emptively offer 
alternative treatments.  
 
The success of this approach is dependent on the efficacy and selectivity of an agent for 
targeting the aberrant AR population. Preliminary data suggest that positive AR-V7 status is not 
necessarily associated with resistance to taxanes  10. Taxane chemotherapy might not be select
ively effective in 
AR-aberrant cancers but could offer an opportunity for improving the treatment of this 
population of men. New agents designed to target the AR lacking the LBD are in 
development11,12 and could offer an opportunity to improve outcomes for these patients.  
 
Whether the presence of aberrant AR is uniformly associated with treatment resistance to AR- 
directed therapy is not known. A study by Bernemann et al.13 reported that some 
patients (4/21) with putatively AR-V7-positive CTCs13 achieved 50% PSA level reductions 
when treated with abiraterone or enzalutamide, although these biochemical 
responses were relatively short-lived. Preliminary data from other studies support these 
findings with occasional PSA declines reported in patients with AR-V7-positive prostate cancer 1
4. Most data support the notion that AR-V7, similar to AR genomic aberrations15 10, 
could be late events involved in treatment resistance 
that are often subclonal. For example both AR-V7-negative and AR-V7-positive CTCs are 
sometimes detected in the same patient16, which could lead to clinical scenarios in which 
responses are variable or PSA levels decline briefly;  however overall, the duration of 
benefit for patients with CTCs expressing AR-V7 is short . Data from patients with 
 
 
AR gene aberrations detected in ccfDNA have shown similar results, with some patients 
exhibiting a decline in PSA concentrations that generally proves to be more transient than 
patients with normal AR detected in ccfDNA 6.  The association of AR-V7 
expression with resistance could be dose-dependent or contingent upon coexisting factors and 
further stratification could improve prediction. However, this multi-hit scenario would still 
suggest that AR-V7-expressing cancers are more likely to develop resistance sooner than 
those that do not. Thus, we agree with Bernemann and colleagues13 that the presence of AR- 
V7 in CTCs does not necessarily preclude PSA responses to abiraterone or enzalutamide, but 
the durability of such responses must also be evaluated before concluding that these patients 
derive meaningful clinical benefit from these novel hormonal agents. In this context, swimmers 
plots could be helpful to show the duration of treatment effect in small cohorts and enable 
appreciation of short benefit in patients despite a decline in PSA concentrations. In the paper 
by Bernemann and co-workers 13, the longest PSA response to novel AR-targeting therapy in  
patients with AR-V7-positive CTCs was 6.2 months, which is considerably shorter 
than the median PSA progression-free survival expected with these agents in this setting. 
Finally, interpretation of the results depends on robust and accurate detection of the biomarker i
n question by using analytically validated biomarker assays before applying these to 
a clinical setting. Whether the assay performed by Bernemann et al.13 was carefully validated 
and standardized  for this clinical study is unclear, and the results should, therefore, be interpret
ed with some degree of caution. 
 
In conclusion, treatment selection based on AR-V7 status remains an experimental 
approach that should not be conducted outside the setting of a clinical trial at the present time. 
The clinical utility of detecting AR-V7 (in CTCs, cell-free nucleic acids or tumour tissue) will rely 
on robust analytical validation of each biomarker assay and will depend on alternative 
treatment options and clinical trials to address this challenge in a prospective fashion. 
 Before the availability of such conclusive results, patients with AR-aberrant disease should cert
ainly be considered for abiraterone or enzalutamide treatment in the appropriate 
clinical setting.  
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